MedTrace Logo

A Study of SPY003-207 in Healthy Volunteers

NCT06873724 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2026-03-20

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

SPY003-207

Experimental

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Altasciences Company Inc.

    collaborator INDUSTRY

  • Spyre Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Deanna Nguyen, MD · Spyre Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-10
Primary Completion
2026-11-18
Completion
2026-11-18
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06873724 on ClinicalTrials.gov